Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun 30:6:174.
doi: 10.1186/1471-2407-6-174.

Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database

Affiliations

Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database

Akihiko Gemma et al. BMC Cancer. .

Abstract

Background: The effect of current therapies in improving the survival of lung cancer patients remains far from satisfactory. It is consequently desirable to find more appropriate therapeutic opportunities based on informed insights. A molecular pharmacological analysis was undertaken to design an improved chemotherapeutic strategy for advanced lung cancer.

Methods: We related the cytotoxic activity of each of commonly used anti-cancer agents (docetaxel, paclitaxel, gemcitabine, vinorelbine, 5-FU, SN38, cisplatin (CDDP), and carboplatin (CBDCA)) to corresponding expression pattern in each of the cell lines using a modified NCI program.

Results: We performed gene expression analysis in lung cancer cell lines using cDNA filter and high-density oligonucleotide arrays. We also examined the sensitivity of these cell lines to these drugs via MTT assay. To obtain our reproducible gene-drug sensitivity correlation data, we separately analyzed two sets of lung cancer cell lines, namely 10 and 19. In our gene-drug correlation analyses, gemcitabine consistently belonged to an isolated cluster in a reproducible fashion. On the other hand, docetaxel, paclitaxel, 5-FU, SN-38, CBDCA and CDDP were gathered together into one large cluster.

Conclusion: These results suggest that chemotherapy regimens including gemcitabine should be evaluated in second-line chemotherapy in cases where the first-line chemotherapy did not include this drug. Gene expression-drug sensitivity correlations, as provided by the NCI program, may yield improved therapeutic options for treatment of specific tumor types.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clustered image map (CIM) relating drug activity to gene expression in lung cancer cell lines – Experiment 1. (A) using filter array, (B) using GeneChip. The cluster trees of drugs (y axis) and gene expression (x axis) were shown in the CIM. Each block of colors represents correlations between clusters of genes and drugs; red (high positive correlation) and blue (negative correlation). In this analysis, gemcitabine belonged to an isolated cluster (Fig. 1A,B). GEM; gemcitabine, PAC; paclitaxel, DOC; docetaxel, VIN; vinorelbine
Figure 2
Figure 2
Clustered image map (CIM) relating drug activity to gene expression in NSCLC cell lines – Experiment 1. (A) using filter array, (B) using GeneChip. The cluster trees of drugs (y axis) and gene expression (x axis) were shown in the CIM. Each block of colors represents correlations between clusters of genes and drugs; red (high positive correlation) and blue (negative correlation). In this gemcitabine belonged to an isolated cluster (Fig. 2A,B). GEM; gemcitabine, PAC; paclitaxel, DOC; docetaxel, VIN; vinorelbine
Figure 3
Figure 3
Clustered image map (CIM) relating drug activity to gene expression in lung cancer cell lines using GeneChip – Experiment 2. (A) all lung cancer cell lines, (B) NSCLC. The cluster trees of drugs (y axis) and gene expression (x axis) were shown in the CIM. Each block of colors represents correlations between clusters of genes and drugs; red (high positive correlation) and blue (negative correlation). In this analysis, gemcitabine belonged to an isolated cluster (Fig. 3A,B). GEM; gemcitabine, PAC; paclitaxel, DOC; docetaxel, VIN; vinorelbine

Similar articles

Cited by

References

    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98. doi: 10.1056/NEJMoa011954. - DOI - PubMed
    1. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623–631. - PubMed
    1. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103. - PubMed
    1. Smit EF, Mattson K, von Pawel J, Manegold C, Clarke S, Postmus PE. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol. 2003;14:455–460. doi: 10.1093/annonc/mdg099. - DOI - PubMed
    1. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods. 1999;303:179–205. - PubMed

Publication types

MeSH terms